L-Glutamine 用于 Irritable Bowel Syndrome (IBS)
CPilot RCTs suggest glutamine (5 g TID) reduces intestinal permeability and IBS-D symptoms in post-infectious IBS. Promising but needs larger trials.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
结论
Pilot RCTs suggest glutamine (5 g TID) reduces intestinal permeability and IBS-D symptoms in post-infectious IBS. Promising but needs larger trials.
Key Study Findings
Other
Unraveling the active ingredients and molecular mechanisms of Qinghua Changyan granule against irritable bowel syndrome …
Dose: None
vs: None
Outcome: IBS-D symptom relief via gut microbiota and glutamine …
效果: None
None
研究人群: animal model of IBS with diarrhea
Other
n=25
4 weeks
Effect of probiotic administration of Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 …
Dose: Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917
vs: phosphate-buffered saline (PBS)
Outcome: visceral hypersensitivity (abdominal withdrawal reflex scores)
效果: None
p<0.05
研究人群: female rats with water avoidance stress-induced IBS-D model
Other
n=62
[Study on activation mechanism of SGCs in representation along the distribution of stomach meridian in …
Dose: None
vs: Control group (no citrobacter)
Outcome: SGC activation in DRG segments
效果: None
P<0.05 to P<0.01
研究人群: Male C57BL/6 mice (IBS-D model)
Review
Intestinal Barrier Impairment, Preservation, and Repair: An Update.
Dose: None
vs: None
Outcome: Intestinal barrier preservation and repair
效果: None
None
研究人群: IBD and IBS patients (review)
Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None
vs: None
Outcome: Cholesterol levels
效果: None
None
研究人群: Mouse model
In Vitro
Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability …
Dose: None
vs: None
Outcome: inflammation markers
效果: None
None
研究人群: Mice
Key Statistics
2
研究数量
150
受试者
↑
Positive
C
等级
Referenced Papers
Fitoterapia
2026
1 次引用
Journal of the …
2026
Zhongguo zhen jiu …
2025
Nutrients
2024
47 次引用
Cannabis and cannabinoid …
2024
10 次引用
International journal of …
2023
9 次引用
Journal of gastroenterology
2022
23 次引用
NeuroImage. Clinical
2022
8 次引用
Digestion
2021
29 次引用
Frontiers in nutrition
2021
17 次引用
Medicine
2021
Nutrition research (New …
2020
42 次引用
World journal of …
2020
11 次引用
Gut
2019
148 次引用
Metabolomics : Official …
2019
41 次引用
Pain
2019
23 次引用
Scientific reports
2019
14 次引用
Gut
2019
5 次引用
[Not Available].
RCT
Praxis
2018
Current opinion in …
2017
71 次引用
JPEN. Journal of …
2016
44 次引用
Gastroenterology
2015
17 次引用
Frontline gastroenterology
2012
20 次引用
The American journal …
2011
48 次引用
Clinical nutrition (Edinburgh, …
2011
12 次引用
MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome.
Other
Gut
2010
263 次引用
Clinics (Sao Paulo, …
2010
47 次引用
Zhong xi yi …
2009
6 次引用
Journal of clinical …
2008
73 次引用
Nutrition in clinical …
2008
42 次引用
Journal of proteome …
2006
80 次引用
Medycyna wieku rozwojowego
2004
1 次引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
常用剂量
- general:
- 5-15 g/day
- ibsdsupport:
- 5 g three times daily (15 g/day total)
- postexercisegut:
- 0.25-0.9 g/kg before intense exercise
- gutbarriersupport:
- 0.5 g/kg/day (approximately 30-40 g/day for adults)
上限： Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
研究中使用的剂量
| 剂量 | 持续时间 | 效果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 | 4 weeks | Positive | 25 |
| None | -- | Mixed | 62 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Negative | 75 |
最佳服用时间： Between meals or before exercise; divide doses throughout the day
Safety & Side Effects
已报告的副作用
- ⚠ Mild gastrointestinal discomfort at high doses
- ⚠ Headache
- ⚠ Dizziness at very high doses
- ⚠ Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)
已知相互作用
- ● Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
- ● Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
- ● Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)
可耐受最高摄入量： Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。
Frequently Asked Questions
Does L-Glutamine help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is limited but promising evidence that L-Glutamine may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is C (Some Evidence).
How much L-Glutamine should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-Glutamine?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-Glutamine and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.
Related Evidence
其他成分用于 Irritable Bowel Syndrome (IBS)
L-Glutamine 用于其他健康状况
FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。